- Krystal Biotech Inc KRYS announced that data from the pivotal Phase 3 (GEM-3) trial of beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa (DEB) had been published in the New England Journal of Medicine (NEJM).
- The 31-patient study showed complete wound healing at six months occurred in 67.4% of B-VEC wounds compared to 21.6% for placebo.
- Related: Krystal Biotech's Subsidiary Posts Durability Data For Fine Line, Wrinkles.
- Complete wound healing at three months occurred in 70.6% of the wounds exposed to B-VEC compared to 19.7% of those exposed to placebo.
- The FDA accepted the marketing application for B-VEC under the Priority Review designation, and the Prescription Drug User Fee Act action date is February 17, 2023.
- Price Action: KRYS shares closed at $77.65 on Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
